Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

By Sawako Suzuki, Tomoaki Tanaka, M. Poyurovsky, Hidekazu Nagano, T. Mayama, S. Ohkubo, M. Lokshin, H. Hosokawa, T. Nakayama, Yutaka Suzuki and 6 more. Proceedings of the National Academy of Sciences of the United States of America, 2010

673 citations recorded by the source corpus.

Subfields: Biochemistry, Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/6ec3e4d57cf664d1c7b966ce85f1ecc6a681b82a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biochemistry

1. C. V. Dang
2. Ralph J. Deberardinis
3. Navdeep S. Chandel
4. S. Weinberg

In Cancer Research

1. C. V. Dang
2. Ralph J. Deberardinis
3. Ping Gao
4. Huafeng Zhang
5. Zhaoyong Li
6. C. Hensley
7. Ajla T. Wasti
8. I. Harris

In Oncology

1. W. Gu
2. Yingming Zhao
3. N. Kon
4. Ping Gao
5. C. V. Dang
6. M. Guo
7. Haolan Wang
8. Yongheng Chen

Citations in the corpus

• Glutaminolysis: A Hallmark of Cancer Metabolism. (2017, background): “The tumor suppressor p53 activates GLS2 expression and removes intracellular reactive oxygen species (ROS) to protect cells from genomic damage (Figure 3) (45, 46).”
• Tumor suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence (2012, positive): “Notably, GLS2 is downregulated in human cancer, and GLS2 overexpression reduces the in vitro proliferation and colony-forming potential of tumor cells (Hu et al., 2010; Suzuki et al., 2010).”
• Signal transduction in cancer. (2015, neutral): “p53 also regulates glutaminase 2, a metabolic enzyme that controls production of glutamate, which is converted to a-ketoglutarate for mitochondrial respiration and, importantly, glutathione, a critical cellular antioxidant (Hu et al. 2010; Suzuki et al. 2010).”
• The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation (2011, background): “Although recent studies indicate that the tumor suppressor p53 is required for the induction of GLS2 in a human tumor cell line (Hu et al., 2010; Suzuki et al., 2010),”
• Targeting mitochondrial glutaminase activity inhibits oncogenic transformation (2010, positive): “Recently, it has been shown that the expression of a distinct form of glutaminase, referred to as the liver-type enzyme or GLS2, was substantially decreased in liver cancer cells and that its overexpression reduced colony formation (Hu et al., 2010; Suzuki et al., 2010).”
• Glutamine and cancer: cell biology, physiology, and clinical opportunities. (2013, positive): “In some tissues, GLS2 is a p53 target gene and seems to function in tumor suppression (14).”
• Regulation of cancer cell metabolism (2011, background): “Glutaminase 2 (GLS2) is upregulated by p53 and drives de novo synthesisof GS”
• Targeting p53 pathways: mechanisms, structures and advances in therapy (2023, background): “p53 plays a dual role in inhibiting and promoting the tricarboxylic acid cycle and oxidative phosphorylation.(46,117,118) p53 is also involved in regulating cellular redox reactions and mediating cancer cell death.”